Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Abetimus · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Abetimus sodium (LJP 394) | DRUG | - |
Inclusion Criteria * Diagnosed with SLE * Historical evidence of SLE renal disease * Elevated levels of dsDNA antibodies * Weight of 40 kg or greater Exclusion Criteria * Active SLE renal disease * Use of certain anti-inflammatory or cytotoxic therapies or therapeutic interventions during the mon...
Abetimus is an investigational small molecule being developed for immunologic diseases, specifically lupus kidney disease. It is being studied in systemic lupus erythematosus with lupus nephritis and lupus glomerulonephritis. The drug is not approved and remains in clinical development.
Abetimus is a small molecule being developed for immunologic diseases. Its specific molecular target has not been disclosed in the available information. The drug is being studied in lupus nephritis, a complication of systemic lupus erythematosus.
Abetimus is being developed by Innoviva, Inc., a company traded on the NASDAQ under the ticker INVA. The drug is currently in Phase 3 clinical development for immunologic diseases, specifically lupus kidney disease.
Abetimus is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is being studied for lupus kidney disease.
Abetimus has one completed Phase 3 clinical trial, NCT00035308, which studied the safety and efficacy of LJP 394 (Abetimus sodium) to treat lupus kidney disease. The trial enrolled 330 participants and was conducted in multiple countries including the United States, Canada, and European nations.
Yes, Abetimus is also known as LJP 394 and Abetimus sodium. The completed Phase 3 clinical trial NCT00035308 was titled 'Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease,' confirming these names refer to the same drug.